| Company Name | Bayer Taiwan |
|---|---|
| Protocol Number | 20324 |
| Title of Study | ON-TRK: PrOspective Non-interventional study in patients with locally advanced or metastatic TRK fusion cancer treated with Larotrectinib / ON-TRK |
| Primary Objective | The primary objective of this study is to describe the safety of larotrectinib in adult and pediatric patients with locally advanced or metastatic TRK fusion cancer, including incidences of all treatment-emergent adverse events (TEAEs) in real-world practice conditions. |
| Number of Sites | 6 |
| Period of Study | From：Study period of Global wise: Q2 2020 – Q2 2030；Study Period of Taiwan: Apr 2023 – Q2 2030 to：For all cohorts except the pediatric cohort : Q2 2027；For the pediatric cohort: Q2 2030 |
| Number of Patients | 300人 |
| IRB Approval Date | 13 Aug 2022 |
| Publication Plan / Date | Q2 2030 |
